Sub menu

 

 

Novartis Pharmaceuticals Australia Pty Limited

Regulatory activities for this sponsor.

Type

Date

30 result(s) found, displaying 1 to 10

  • Pluvicto (Lutetium (177Lu) vipivotide tetraxetan)

    Prescription medicine decision summary
    Pluvicto (Lutetium (177Lu) vipivotide tetraxetan) has been approved for the treatment of adult patients with prostate cancer who have received prior treatments.

  • AusPAR: Cosentyx

    Australian public assessment report (AusPar)
    AusPAR for Cosentyx (secukinumab) for the treatment of plaque psoriasis, psoriatic arthritis and axial spondyloarthritis etc.

  • AusPAR: Inclisiran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Inclisiran

  • Leqvio

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Zolgensma

    Prescription medicine decision summary
    TGA decision: Zolgensma (onasemnogene abeparvovec) is approved to treat patients less than 9 months old with symptomatic/pre-symptomatic SMA.

  • AusPAR: Deferasirox

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Deferasirox

  • AusPAR: Imatinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Imatinib

  • AusPAR: Nabiximols

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Nabiximols